API

Bevacizumab (400mg)

Drug classification

Antineoplastic agents (monoclonal antibody, angiogenesis inhibitor).

Dosage form

Injectable solution in a vial.

API strength per dosage

Avastin 400mg Injection contains 400 mg of Bevacizumab per vial.

Dose

For adults, Bevacizumab (Avastin) is typically administered at a dose of 5 to 15 mg/kg every 2 to 3 weeks, depending on the specific cancer type and treatment regimen. Pediatric dosing and adjustments for special populations should be determined by a healthcare provider based on individual needs and conditions.

Mechanism of action

Bevacizumab binds to vascular endothelial growth factor (VEGF), inhibiting its interaction with receptors (VEGFR-1 and VEGFR-2) on endothelial cells, thereby preventing angiogenesis, which reduces tumor blood supply and growth.

Indications

Cancer of colon and rectum Non-small cell lung cancer Kidney cancer Brain tumor Ovarian cancer Cervical cancer

Side effects

Rectal bleeding Taste change Headache Nosebleeds Back pain Dry skin High blood pressure Protein in urine Inflammation of the nose

Pregnancy category

Category C

Precautions

Monitor for hypertension, proteinuria, infusion reactions, gastrointestinal perforations, wound healing complications, hemorrhage, thromboembolic events, congestive heart failure, reversible posterior leukoencephalopathy syndrome, neutropenia, ovarian failure, embryofetal toxicity; avoid in pregnancy, caution in surgery and invasive procedures, assess renal function and urine protein.

Contraindications

Hypersensitivity to bevacizumab or excipients, pregnancy, uncontrolled hypertension, recent surgery, serious hemorrhage, gastrointestinal perforation, congestive heart failure, thromboembolic events, wound healing complications.